ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Non-invasive Tumor Detection Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-0P17877
Home | Market Reports | Health| Health Conditions| Cancer
Global Non invasive Tumor Detection Market Research Report 2024
BUY CHAPTERS

Global Non-invasive Tumor Detection Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-0P17877
Report
October 2025
Pages:119
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Nucleix
Nonacus, Inc.
Natera
Penn Medicine
bioAffinity Technologies
miR Scientific

Non-invasive Tumor Detection Market

The global Non-invasive Tumor Detection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Prostate Cancer accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Non-invasive Tumor Detection leading manufacturers including Datar Cancer Genetics, Nucleix, bioAffinity Technologies, miR Scientific, Nonacus, Natera, Penn Medicine, etc., dominate supply; the top five capture approximately % of global revenue, with Datar Cancer Genetics leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Non-invasive Tumor Detection market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Non-invasive Tumor Detection Market Report

Report Metric Details
Report Name Non-invasive Tumor Detection Market
Segment by Type
  • DNA
  • RNA
Segment by Application
  • Prostate Cancer
  • Bladder Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Datar Cancer Genetics, Nucleix, bioAffinity Technologies, miR Scientific, Nonacus, Natera, Penn Medicine
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Non-invasive Tumor Detection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Non-invasive Tumor Detection Market report?

Ans: The main players in the Non-invasive Tumor Detection Market are Datar Cancer Genetics, Nucleix, bioAffinity Technologies, miR Scientific, Nonacus, Natera, Penn Medicine

What are the Application segmentation covered in the Non-invasive Tumor Detection Market report?

Ans: The Applications covered in the Non-invasive Tumor Detection Market report are Prostate Cancer, Bladder Cancer, Pancreatic Cancer, Breast Cancer, Gastric Cancer, Others

What are the Type segmentation covered in the Non-invasive Tumor Detection Market report?

Ans: The Types covered in the Non-invasive Tumor Detection Market report are DNA, RNA

1 Study Coverage
1.1 Introduction to Non-invasive Tumor Detection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Non-invasive Tumor Detection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 DNA
1.2.3 RNA
1.3 Market Segmentation by Application
1.3.1 Global Non-invasive Tumor Detection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Prostate Cancer
1.3.3 Bladder Cancer
1.3.4 Pancreatic Cancer
1.3.5 Breast Cancer
1.3.6 Gastric Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Non-invasive Tumor Detection Revenue Estimates and Forecasts 2020-2031
2.2 Global Non-invasive Tumor Detection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Non-invasive Tumor Detection Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Non-invasive Tumor Detection Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 DNA Market Size by Players
3.3.2 RNA Market Size by Players
3.4 Global Non-invasive Tumor Detection Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Non-invasive Tumor Detection Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Non-invasive Tumor Detection Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Non-invasive Tumor Detection Market Size by Type (2020-2031)
6.4 North America Non-invasive Tumor Detection Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Non-invasive Tumor Detection Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Non-invasive Tumor Detection Market Size by Type (2020-2031)
7.4 Europe Non-invasive Tumor Detection Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Non-invasive Tumor Detection Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Non-invasive Tumor Detection Market Size by Type (2020-2031)
8.4 Asia-Pacific Non-invasive Tumor Detection Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Non-invasive Tumor Detection Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Non-invasive Tumor Detection Market Size by Type (2020-2031)
9.4 Central and South America Non-invasive Tumor Detection Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Non-invasive Tumor Detection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Non-invasive Tumor Detection Market Size by Type (2020-2031)
10.4 Middle East and Africa Non-invasive Tumor Detection Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Non-invasive Tumor Detection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Datar Cancer Genetics
11.1.1 Datar Cancer Genetics Corporation Information
11.1.2 Datar Cancer Genetics Business Overview
11.1.3 Datar Cancer Genetics Non-invasive Tumor Detection Product Features and Attributes
11.1.4 Datar Cancer Genetics Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.1.5 Datar Cancer Genetics Non-invasive Tumor Detection Revenue by Product in 2024
11.1.6 Datar Cancer Genetics Non-invasive Tumor Detection Revenue by Application in 2024
11.1.7 Datar Cancer Genetics Non-invasive Tumor Detection Revenue by Geographic Area in 2024
11.1.8 Datar Cancer Genetics Non-invasive Tumor Detection SWOT Analysis
11.1.9 Datar Cancer Genetics Recent Developments
11.2 Nucleix
11.2.1 Nucleix Corporation Information
11.2.2 Nucleix Business Overview
11.2.3 Nucleix Non-invasive Tumor Detection Product Features and Attributes
11.2.4 Nucleix Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.2.5 Nucleix Non-invasive Tumor Detection Revenue by Product in 2024
11.2.6 Nucleix Non-invasive Tumor Detection Revenue by Application in 2024
11.2.7 Nucleix Non-invasive Tumor Detection Revenue by Geographic Area in 2024
11.2.8 Nucleix Non-invasive Tumor Detection SWOT Analysis
11.2.9 Nucleix Recent Developments
11.3 bioAffinity Technologies
11.3.1 bioAffinity Technologies Corporation Information
11.3.2 bioAffinity Technologies Business Overview
11.3.3 bioAffinity Technologies Non-invasive Tumor Detection Product Features and Attributes
11.3.4 bioAffinity Technologies Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.3.5 bioAffinity Technologies Non-invasive Tumor Detection Revenue by Product in 2024
11.3.6 bioAffinity Technologies Non-invasive Tumor Detection Revenue by Application in 2024
11.3.7 bioAffinity Technologies Non-invasive Tumor Detection Revenue by Geographic Area in 2024
11.3.8 bioAffinity Technologies Non-invasive Tumor Detection SWOT Analysis
11.3.9 bioAffinity Technologies Recent Developments
11.4 miR Scientific
11.4.1 miR Scientific Corporation Information
11.4.2 miR Scientific Business Overview
11.4.3 miR Scientific Non-invasive Tumor Detection Product Features and Attributes
11.4.4 miR Scientific Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.4.5 miR Scientific Non-invasive Tumor Detection Revenue by Product in 2024
11.4.6 miR Scientific Non-invasive Tumor Detection Revenue by Application in 2024
11.4.7 miR Scientific Non-invasive Tumor Detection Revenue by Geographic Area in 2024
11.4.8 miR Scientific Non-invasive Tumor Detection SWOT Analysis
11.4.9 miR Scientific Recent Developments
11.5 Nonacus
11.5.1 Nonacus Corporation Information
11.5.2 Nonacus Business Overview
11.5.3 Nonacus Non-invasive Tumor Detection Product Features and Attributes
11.5.4 Nonacus Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.5.5 Nonacus Non-invasive Tumor Detection Revenue by Product in 2024
11.5.6 Nonacus Non-invasive Tumor Detection Revenue by Application in 2024
11.5.7 Nonacus Non-invasive Tumor Detection Revenue by Geographic Area in 2024
11.5.8 Nonacus Non-invasive Tumor Detection SWOT Analysis
11.5.9 Nonacus Recent Developments
11.6 Natera
11.6.1 Natera Corporation Information
11.6.2 Natera Business Overview
11.6.3 Natera Non-invasive Tumor Detection Product Features and Attributes
11.6.4 Natera Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.6.5 Natera Recent Developments
11.7 Penn Medicine
11.7.1 Penn Medicine Corporation Information
11.7.2 Penn Medicine Business Overview
11.7.3 Penn Medicine Non-invasive Tumor Detection Product Features and Attributes
11.7.4 Penn Medicine Non-invasive Tumor Detection Revenue and Gross Margin (2020-2025)
11.7.5 Penn Medicine Recent Developments
12 Non-invasive Tumor DetectionIndustry Chain Analysis
12.1 Non-invasive Tumor Detection Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Non-invasive Tumor Detection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Non-invasive Tumor Detection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Nucleix
Nonacus, Inc.
Natera
Penn Medicine
bioAffinity Technologies
miR Scientific
List of Tables
 Table 1. Global Non-invasive Tumor Detection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Non-invasive Tumor Detection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Non-invasive Tumor Detection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Non-invasive Tumor Detection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Non-invasive Tumor Detection Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Non-invasive Tumor Detection Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Non-invasive Tumor Detection by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-invasive Tumor Detection as of 2024)
 Table 11. Global Non-invasive Tumor Detection Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Non-invasive Tumor Detection Companies Headquarters
 Table 13. Global Non-invasive Tumor Detection Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Non-invasive Tumor Detection Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Non-invasive Tumor Detection Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Non-invasive Tumor Detection Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Non-invasive Tumor Detection Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Non-invasive Tumor Detection High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Non-invasive Tumor Detection Growth Accelerators and Market Barriers
 Table 25. North America Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Non-invasive Tumor Detection Growth Accelerators and Market Barriers
 Table 27. Europe Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Non-invasive Tumor Detection Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Non-invasive Tumor Detection Investment Opportunities and Key Challenges
 Table 31. Central and South America Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Non-invasive Tumor Detection Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Non-invasive Tumor Detection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Datar Cancer Genetics Corporation Information
 Table 35. Datar Cancer Genetics Description and Major Businesses
 Table 36. Datar Cancer Genetics Product Features and Attributes
 Table 37. Datar Cancer Genetics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Datar Cancer Genetics Revenue Proportion by Product in 2024
 Table 39. Datar Cancer Genetics Revenue Proportion by Application in 2024
 Table 40. Datar Cancer Genetics Revenue Proportion by Geographic Area in 2024
 Table 41. Datar Cancer Genetics Non-invasive Tumor Detection SWOT Analysis
 Table 42. Datar Cancer Genetics Recent Developments
 Table 43. Nucleix Corporation Information
 Table 44. Nucleix Description and Major Businesses
 Table 45. Nucleix Product Features and Attributes
 Table 46. Nucleix Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Nucleix Revenue Proportion by Product in 2024
 Table 48. Nucleix Revenue Proportion by Application in 2024
 Table 49. Nucleix Revenue Proportion by Geographic Area in 2024
 Table 50. Nucleix Non-invasive Tumor Detection SWOT Analysis
 Table 51. Nucleix Recent Developments
 Table 52. bioAffinity Technologies Corporation Information
 Table 53. bioAffinity Technologies Description and Major Businesses
 Table 54. bioAffinity Technologies Product Features and Attributes
 Table 55. bioAffinity Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. bioAffinity Technologies Revenue Proportion by Product in 2024
 Table 57. bioAffinity Technologies Revenue Proportion by Application in 2024
 Table 58. bioAffinity Technologies Revenue Proportion by Geographic Area in 2024
 Table 59. bioAffinity Technologies Non-invasive Tumor Detection SWOT Analysis
 Table 60. bioAffinity Technologies Recent Developments
 Table 61. miR Scientific Corporation Information
 Table 62. miR Scientific Description and Major Businesses
 Table 63. miR Scientific Product Features and Attributes
 Table 64. miR Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. miR Scientific Revenue Proportion by Product in 2024
 Table 66. miR Scientific Revenue Proportion by Application in 2024
 Table 67. miR Scientific Revenue Proportion by Geographic Area in 2024
 Table 68. miR Scientific Non-invasive Tumor Detection SWOT Analysis
 Table 69. miR Scientific Recent Developments
 Table 70. Nonacus Corporation Information
 Table 71. Nonacus Description and Major Businesses
 Table 72. Nonacus Product Features and Attributes
 Table 73. Nonacus Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Nonacus Revenue Proportion by Product in 2024
 Table 75. Nonacus Revenue Proportion by Application in 2024
 Table 76. Nonacus Revenue Proportion by Geographic Area in 2024
 Table 77. Nonacus Non-invasive Tumor Detection SWOT Analysis
 Table 78. Nonacus Recent Developments
 Table 79. Natera Corporation Information
 Table 80. Natera Description and Major Businesses
 Table 81. Natera Product Features and Attributes
 Table 82. Natera Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Natera Recent Developments
 Table 84. Penn Medicine Corporation Information
 Table 85. Penn Medicine Description and Major Businesses
 Table 86. Penn Medicine Product Features and Attributes
 Table 87. Penn Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Penn Medicine Recent Developments
 Table 89. Raw Materials Key Suppliers
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. Non-invasive Tumor Detection Product Picture
 Figure 2. Global Non-invasive Tumor Detection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. DNA Product Picture
 Figure 4. RNA Product Picture
 Figure 5. Global Non-invasive Tumor Detection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Prostate Cancer
 Figure 7. Bladder Cancer
 Figure 8. Pancreatic Cancer
 Figure 9. Breast Cancer
 Figure 10. Gastric Cancer
 Figure 11. Others
 Figure 12. Non-invasive Tumor Detection Report Years Considered
 Figure 13. Global Non-invasive Tumor Detection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Non-invasive Tumor Detection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 16. Global Non-invasive Tumor Detection Revenue Market Share by Region (2020-2031)
 Figure 17. Global Non-invasive Tumor Detection Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. DNA Revenue Market Share by Player in 2024
 Figure 20. RNA Revenue Market Share by Player in 2024
 Figure 21. Global Non-invasive Tumor Detection Revenue Market Share by Type (2020-2031)
 Figure 22. Global Non-invasive Tumor Detection Revenue Market Share by Application (2020-2031)
 Figure 23. North America Non-invasive Tumor Detection Revenue YoY (2020-2031) & (US$ Million)
 Figure 24. North America Top 5 Players Non-invasive Tumor Detection Revenue (US$ Million) in 2024
 Figure 25. North America Non-invasive Tumor Detection Revenue (US$ Million) by Type (2020 - 2031)
 Figure 26. North America Non-invasive Tumor Detection Revenue (US$ Million) by Application (2020-2031)
 Figure 27. US Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 28. Canada Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 29. Mexico Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 30. Europe Non-invasive Tumor Detection Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. Europe Top 5 Players Non-invasive Tumor Detection Revenue (US$ Million) in 2024
 Figure 32. Europe Non-invasive Tumor Detection Revenue (US$ Million) by Type (2020-2031)
 Figure 33. Europe Non-invasive Tumor Detection Revenue (US$ Million) by Application (2020-2031)
 Figure 34. Germany Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 35. France Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 36. U.K. Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 37. Italy Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 38. Russia Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Non-invasive Tumor Detection Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Top 8 Players Non-invasive Tumor Detection Revenue (US$ Million) in 2024
 Figure 41. Asia-Pacific Non-invasive Tumor Detection Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Asia-Pacific Non-invasive Tumor Detection Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Indonesia Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 44. Japan Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 45. South Korea Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 46. Australia Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 47. India Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 48. Indonesia Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 49. Vietnam Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 50. Malaysia Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 51. Philippines Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 52. Singapore Non-invasive Tumor Detection Revenue (2020-2031) & (US$ Million)
 Figure 53. Central and South America Non-invasive Tumor Detection Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Central and South America Top 5 Players Non-invasive Tumor Detection Revenue (US$ Million) in 2024
 Figure 55. Central and South America Non-invasive Tumor Detection Revenue (US$ Million) by Type (2020-2031)
 Figure 56. Central and South America Non-invasive Tumor Detection Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Brazil Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 58. Argentina Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 59. Middle East and Africa Non-invasive Tumor Detection Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Middle East and Africa Top 5 Players Non-invasive Tumor Detection Revenue (US$ Million) in 2024
 Figure 61. South America Non-invasive Tumor Detection Revenue (US$ Million) by Type (2020-2031)
 Figure 62. Middle East and Africa Non-invasive Tumor Detection Revenue (US$ Million) by Application (2020-2031)
 Figure 63. GCC Countries Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 64. Israel Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 65. Egypt Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 66. South Africa Non-invasive Tumor Detection Revenue (2020-2025) & (US$ Million)
 Figure 67. Non-invasive Tumor Detection Industry Chain Mapping
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Solid Tumor Detection Market Research Report 2024
Global Non Invasive Colon Cancer Screening Market Research Report 2024
Noninvasive Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Circulating Tumor Cell Detector Market Research Report 2024
Global Tumor Markers Detection Kit Market Research Report 2025
Global Non invasive Cancer Diagnosis Market Research Report 2024
Global Multi Cancer Early Detection Market Research Report 2025
Non Invasive Cancer Diagnostics Market
Global Tumor Marker Detection Products Market Insights Forecast to 2030
Global Non Invasive Medical Device Market Research Report 2024
Global Cancer Screening Technology Market Research Report 2024
Global Cancer Imaging System Market Research Report 2025
Global Noninvasive Diagnostics Market Insights Forecast to 2030
Global Non invasive Air Bubble Detector Market Research Report 2025
Global Tumor Diagnosis Solutions Market Research Report 2025
Circulating Tumor Cell Detection Instrument Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non ionizing Radiation Detection Measurement and Safety Market Insights Forecast to 2030
Global Non Invasive Helicobacter Pylori Detection Market Research Report 2025
Next Generation Cancer Diagnostics Market
Global Non invasive Diagnosis Market Research Report 2025

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions